文献速递消化系统肿瘤

DEEPER试验最终分析:m-FOLFOXIRI联合西妥昔单抗对比贝伐珠单抗在RAS/BRAF野生型mCRC的长期生存

Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.
PubMed 文献 · J Clin Oncol · 2026-08-27

DEEPER随机II期试验最终分析比较m-FOLFOXIRI联合西妥昔单抗或贝伐珠单抗治疗RAS野生型转移性结直肠癌,按方案集PFS和OS无差异;

要点

  • 按方案集总体PFS和OS无显著差异。
  • RAS/BRAF野生型左半肿瘤患者西妥昔单抗组PFS获益。
  • 探索性亚组男性及肝外转移患者OS可能获益。

核心结论

  • m-FOLFOXIRI联合西妥昔单抗在RAS/BRAF野生型左半mCRC中可能带来更优结局。
  • 总体按方案集PFS和OS无差异,但探索性亚组显示获益信号。

研究设计与样本

  • 随机II期DEEPER试验(jRCTs061180022)最终生存分析。
  • 比较m-FOLFOXIRI联合西妥昔单抗 vs 贝伐珠单抗,按方案集分析PFS和OS。

主要发现

  • 按方案集PFS和OS无差异。
  • 同组中位OS:西妥昔单抗组50.2个月 vs 贝伐珠单抗组40.2个月(HR 0.74,95%CI 0.53-1.05)。

关键数值与推荐

  • RAS/BRAF野生型左半mCRC:西妥昔单抗组中位OS 50.2个月,贝伐珠单抗组40.2个月(HR 0.74,95%CI 0.53-1.05)。

临床怎么用

  • 对RAS/BRAF野生型左半mCRC可考虑m-FOLFOXIRI联合西妥昔单抗以延长PFS。
  • 男性及肝外转移患者可能从西妥昔单抗联合方案中更多获益,需进一步验证。

局限性

  • II期试验,样本量有限。
  • 亚组分析为探索性,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The randomized phase II DEEPER trial (jRCTs061180022) previously reported superior depth of response with modified 5-fluorouracil, leucovorin, oxaliplatin and irinotecan (m-FOLFOXIRI) plus cetuximab versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer (mCRC). Here, we report updated final survival outcomes and exploratory subgroup analyses focusing on RAS/BRAF wild-type and left-sided tumors. Final overall survival (OS) and progression-free survival (PFS) were analyzed in the per-protocol set (PPS) with exploratory subgroup analyses according to the presence of liver-limited disease and sex, using extended follow-up data. There were no differences in PFS and OS in the PPS. In patients with RAS/BRAF wild-type and left-sided tumors, median PFS was longer with cetuximab than with bevacizumab (14.8 v 11.9 months; hazard ratio [HR], 0.71 [95% CI, 0.52 to 0.97]; P = .029). The median OS was 50.2 months for cetuximab and 40.2 months for bevacizumab (HR, 0.74 [95% CI, 0.53 to 1.05]). In the exploratory analyses, cetuximab-based therapy was associated with longer OS in male patients (HR, 0.59; P = .016) and in patients with extrahepatic disease (HR, 0.60; P = .014). In conclusion, the DEEPER trial suggests that m-FOLFOXIRI plus cetuximab achieves superior tumor shrinkage and may be associated with favorable outcomes in selected patients with RAS/BRAF wild-type and left-sided mCRC, with exploratory signals of benefit in male patients and those with extrahepatic disease.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sunakawa Y, Shiozawa M, Watanabe T, et al. Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial. J Clin Oncol. 2026. PMID: 42659588. doi:10.1200/JCO-26-00355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。